Congenital heart diseases are a major part of Costello and cardio-facio-cutaneous syndromes. Subaortic stenosis was reported rarely and Ross operation never in these syndromes. We reported a girl patient whose manifestations were consistent with these syndromes. Distinction between these syndromes was not possible as genetic testing was not carried out. She developed severe neoaortic regurgitation 2.5 years after the Ross operation and died due to the complications of aortic valve replacement. Ross operation may be an unsuitable option in these syndromes due to the possibility of subtle pulmonic valve pathology.
Introduction
The neuro-cardio-facial-cutaneous syndromes consist of neurofibromatosis type 1, Noonan, LEOPARD, Costello and cardio-facio-cutaneous (CFC) syndromes.
Genetic alterations in the RAS-MAPKinase pathway produce these syndromes. Regulation of cellular proliferation, differentiation and survival is the task of this pathway. [1] Psychomotor retardation, congenital heart diseases (CHD), facial abnormalities, short stature, skin problems and cancer predisposition are common findings in these syndromes. [1] However, the responsible genetic mutations are different. HRAS gene mutations are responsible for Costello syndrome while those in several others (BRAF, KRAS, MEK-1 or MEK-2) cause CFC syndrome. [1] We reported on a patient with characteristics in favor of Costello or CFC syndromes. Differentiation between these two entities in this patient was not possible solely on the clinical findings. Unfortunately, genetic testing was not performed before her death. However, Ross operation was reported neither in patients with Costello syndrome nor in those with CFC syndrome to the best of our knowledge.
Case Report
The patient was a girl with subaortic stenosis, keratosis pilaris, growth retardation, nail dystrophy, bitemporal hollowing, macrocephaly and sparse scalp hair 
Discussion
The presented case had certain manifestations such as failure to thrive, CHD, widespread hyperkeratotic skin lesions, sparse hair and relative macrocephaly, which are consistent with both the diagnosis of Costello and CFC syndromes. However, differentiation between these two entities was difficult based only on the clinical findings.
Genetic testing was not performed for this patient.
CHD is common in both syndromes. Cardiac abnormalities were found in 63% of the patients with Costello syndrome, consisting of structural defects in 30% (most commonly pulmonic stenosis), myocardial hypertrophy in 34% and arrhythmias in 33%. [2] Subaortic stenosis was reported in these patients, although only in a few cases. [2] CFC syndrome is accompanied by a cardiac abnormality in around 76% of the patients. [3] Pulmonary valvar stenosis is the leading abnormality in this syndrome as well, being seen in 47%. Hypertrophic cardiomyopathy (40%) and atrial septal defects (23%) follow that abnormality. As far as the authors know, subaortic stenosis as the cardiac manifestation of CFC syndrome was reported only once. [4] Ross operation consists of autografting pulmonary valve in place of the aortic valve and putting a homograft in place of the pulmonary valve. This operation is used when the aortic valve should be replaced and a prosthetic valve is not desirable. Severe autograft dysfunction with 467 patients (3%), requiring reoperation after a mean of 39.3 months. [5] In that of de Kerchove et al., the autograft was reoperated due to severe regurgitation in 18 of 218 patients (8.3%). Mean delay to reoperation was 8.7 and 6 years in the two studied subgroups. [6] We did not see such an occurrence in our patients after Ross operation, as well.
As far as the authors know, this patient is the first patient with either CFC or Costello syndrome on whom a Ross operation was carried out. Relatively rapid destruction of the neoaortic valve (2.5 years) in spite of echocardiographical normality before the operation may be due to a subtle structural pathology in the pulmonary valve. Although it is difficult to come into conclusion based only on one patient, it may be advisable to avoid Ross operation in these patients even if the pulmonary valve seems to be normal echocardiographically.
